This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Healthcare Europe

Making a measurable difference

EliA CCP test and EliA RF isotypes, best-in-class tests that help you get it right the first time

Early diagnosis in rheumatoid arthritis is pivotal but can be challenging

The diverse and overlapping symptoms that can be present in early rheumatoid arthritis (RA) can make diagnosis challenging.1-4

It is well established that early, appropriate, treatment may prevent joint erosion and possibly halt disease progression. However, up to 40% of patients are first misdiagnosed.5,6

Reliable testing can help to:

  • Determine if referral to a specialist is appropriate
  • Ensure effective and timely treatment
  • Improve patient outcomes


Rheumatoid factor (RF) IgM
Recommended as 1st line test in ACR/EULAR criteria7

Decreased titres are associated with a positive
treatment response to methotrexate, parenteral gold and TNFα inhibitors8-16
Anti-CCP antibodies
Detectable years before onset of RA symptoms17
Very sensitive and highly specific in early RA18
Associated with severe disease in early RA17,19
Elevated RF IgA to monitor disease activity
Correlates with disease activity20-22
Indicates poor response to TNF-α inhibitors23
Provides valuable prognostic guidance

In low-prevalence disease, like rheumatoid arthritis, specificity is important

The recommended first-line testing that supports the diagnosis of RA best does include CCP and RF IgM measurements7

However, it’s well established that:

  • Clinical test performance varies by manufacturer
  • The most common marker provided is rheumatoid factor (measuring a mix of isotypes (IgG, IgA and IgM) without characterising individual isotypes) vs. the specific identification of RF IgM

In low-prevalence disease where most tests are expected to be negative, every increase in specificity is important. Higher specificity leads to fewer false positive results.

EliA CCP test – best-in-class, a test you can rely on to help correctly identify rheumatoid arthritis patients

EliA CCP test, validated in a meta-analysis of 83 studies of known or suspected rheumatoid arthritis patients, provides you with a diagnostic test you can rely on.24

Meta-analysis of 83 diagnostic studies containing data on CCP tests in known or suspected RA
patients. A bivariate model was used to produce summary estimates for test sensitivity and specificity.

Based on 2500 patients being tested in a year, when
comparing the superior specificity of EliA CCP test24 to
a test with 90% specificity and a disease prevalence of 1%,
you can expect 148 fewer false positives per year.

EliA RF isotypes – greater certainty of diagnosis

Nephelometry and turbidimetry, the most common methods for testing for rheumatoid factor, cannot measure individual isotypes.25

EliA test is able to measure individual isotypes for rheumatoid factor (Separately measuring RF IgM, IgA and IgG).26

In a study of 290 RA patients, 53% were positive for 3 or more antibodies28

The addition of RF IgM and RF IgA to CCP improves the specificity of testing – if all three are positive, specificity is 100%, and as such a diagnosis of rheumatoid arthritis is very likely.26,27

Sensitivity and specificity of mono- and multi-serology testing EliA, in 190 RA patients and 197 disease controls.26

thermo scientific

The choice is yours

EliA rheumatoid arthritis tests offer you:

  • A testing solution that helps you get it right the first time – in low-prevalence disease, like rheumatoid arthritis, to reduce false positive results, specificity is important; EliA CCP test and RF isotypes offer an outstanding combination of sensitivity and specificity24,26
  • A test you can rely on – EliA CCP test is the best-in-class, a test you can rely on to help correctly identify rheumatoid arthritis patients24
  • Isotypes that offer added confidence – The addition of EliA RF IgM and RF IgA tests to EliA CCP test improves the specificity of testing – if all three are positive the specificity of testing is 100%26,27

Find out more at

© 2019 Thermo Fisher Scientific Inc. All rights reserved.
All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. 69284.AI.EU1.EN.v1.19

1. Kawczyk-Krupka A, et al. Ann Acad Med Siles 2013;67:78-83. 2. Ahmad Y and Bruce I. Collected reports on rheumatic diseases, series 4 (revised). Published by the Arthritis Research Campaign. 2005. 3. Suresh E. J R Soc Med 2004;97:421-424. 4. Price EJ, et al. Rheumatology 2017;56:e24-e48. 5. Santos-Moreno P, et al. Osteoarthritis and Cartilage 2012;20:S165. 6. Santos-Moreno P, et al. Osteoarthritis and Cartilage 2017;25:S219. 7. Aletaha D, et al. Arthritis Rheum 2010;62:2569-2581. 8. Alarcón GS, et al. Arthritis Rheum 1990 Aug;33(8):1156–61. 9. Klaasen R, et al. Rheumatology (Oxford) 2011; 50(8):1487–93. 10. Bruns A, et al. Joint Bone Spine 2009;76(3):248–53. 11. Bobbio-Pallavicini F, et al. Ann Rheum Dis 2007;66(3):302–7. 12. Potter C, et al. Ann Rheum Dis 2009;68(1):69-74. 13. Alessandri C, et al. Ann Rheum Dis 2004;63(10):1218–21. 14. Nozaki Y, et al. Nihon Rinsho Meneki Gakkai Kaishi 2010;33(3):135–41. 15. Canhão H, et al. Rheumatology (Oxford) 2012;51(11):2020–6. 16. Chen HA, et al. Ann Rheum Dis 2006 Jan;65(1):35–9. 17. Kokkonen H, et al. Arthrits Res Ther 2011;13:R13. 18. Egerer K, et al. Dtsch Ärztebl 2009;106(10):159-163. 19. Svard A, et al. Arthritis Res Ther 2008;10:R75. 20. De Angeles V, meroni PL, Rheumatoid Factors. In Schoenfeld Y, Gershwin ME, Meroni PL eds. Autoantibodies 2nd edn. Amsterdam: Elsevier, 2007: 755-62. 21. Shakiba Y, et al. Iran J Allergy Asthma Immunol 2014;13(3):147-156. 22. Jónsson T and Valdimarsson H. Ann Rheum Dis 1993;52:161-164. 23. Bobbio-Pallavicini F, Caporali R, Alpini C, et al. Ann Rheum Dis 2007;66(3):302-307. 24. Matthson Alm L, et al. Clin Exp Rheumatol 2017;36(1):144-152. 25. Nishimura K, et al. Ann Intern Med 2007;146:797-808. 26. Mascialino B, et al. Diagnostic accuracy of serum autoantibodies multi-testing in rheumatoid arthritis and economic consequences across Europe. Presented at EULAR Amsterdam. 13-16 June 2018. 27. Jaskowski T, et al. J Rheumatol 2010; 37: 1582–1588. 28. Sieghart D, et al. Front Immunol 2018; 9: 876.